[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635148":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":32,"overallOfficials":11,"centralContacts":42,"locations":11,"responsibleParty":48,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":11},{"fullName":5,"class":6},"Sohag University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Repigmentation in the vitiliginous area after receiving the treatment and increasing the wnt b catenin marker level in the histopathological specimen",null,"From enrollment to the end of treatment at 16 weeks for each patient",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","FACTORIAL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"INVESTIGATOR","OUTCOMES_ASSESSOR",[23,28],{"label":24,"type":25,"description":11,"interventionNames":26},"Microneedling + minoxidil5%","ACTIVE_COMPARATOR",[27],"Combination Product: Microneedling with Minoxidil5%",{"label":29,"type":25,"description":11,"interventionNames":30},"Microneedling + minoxidil5% +NBUVB",[31,27],"Combination Product: microneedling with minoxidil 5% and NBUVB",[33,38],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"COMBINATION_PRODUCT","microneedling with minoxidil 5% and NBUVB","Micronnedlin depth 1% then topical Minoxidil5% and Narrow Band UVB",[29],{"type":34,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"Microneedling with Minoxidil5%","Microneedling with topical Minoxidil 5%",[24,29],[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Rasha Hesham el dein mohammed, Bachelor","CONTACT","+201111199719","rashahesham15@gmail.com",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Rasha Heshameldien Mohamed","doctor","100635148",false,"NCT07548918","Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo\"","Comparative Clinical and Histopathological Study of Microneedling With Topical Minoxidil 5% Versus Microneedling With Topical Minoxidil 5% Combined With Narrow-Band Ultraviolet B Phototherapy in the Treatment of Stable Vitiligo","Inclusion Criteria:\n\n* Patients with stable non-segmental vitiligo\n* No new lesions\n* No enlargement of existing lesions\n* Patients of both sexes\n* Age 16 years or older\n\nExclusion Criteria:\n\n* Active vitiligo\n* Pregnant or lactating women\n* History of keloid formation\n* Hematological disorders\n* Coagulopathies\n* Use of anticoagulant therapy\n* Use of medications that may prolong bleeding\n* Previous vitiligo treatment in the last 2 months",true,"ALL","16 Years","60 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo.\n\nIt aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo.\n\nVitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact.\n\nThe study also investigates immunohistochemical changes, particularly Wnt\u002Fβ-catenin signaling expression in lesional skin.\n\nThe combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis",[70],"Vitiligo - Macular Depigmentation","NOT_YET_RECRUITING","2026-04-23",{"date":74,"type":75},"2026-04-29","ACTUAL",{"date":77,"type":64},"2026-05-20",{"date":79,"type":64},"2027-10-15",{"name":5,"class":6}]